Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells
Article first published online: 30 DEC 2003
Copyright © 1998 by the American Association for the Study of Liver Diseases
Volume 28, Issue 4, pages 1110–1116, October 1998
How to Cite
Schmidt, W. N., Wu, P., Brashear, D., Klinzman, D., Phillips, M. J., LaBrecque, D. R. and Stapleton, J. T. (1998), Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Hepatology, 28: 1110–1116. doi: 10.1002/hep.510280428
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Manuscript Accepted: 1 JUN 1998
- Manuscript Received: 5 JAN 1998
- National Institutes of Health (W.N.S.), a Merit Review Award of the Veterans Administration (J.T.S.). Grant Number: 1 KO8 A101460-01
- Schering Plough Research Institute (D.R.L., W.N.S., and J.T.S.) Integrated Therapeutics Group, Inc.
- University of Iowa Clinical Research Center (NIH). Grant Number: RR00059
- Dr. Schmidt was also funded by NIH Training. Grant Number: DK07663
Fifty-two patients with chronic hepatitis C virus (HCV) infection were treated with standard doses of interferon alfa-2b. During treatment, HCV RNA detection was studied in samples of whole blood (WB), plasma (Pl), and peripheral blood mononuclear cells (PBMCs). Individuals were classified as sustained responders (SRs), complete responders with relapse (CRs), partial responders (PRs), or nonresponders (NRs) according to normalization of serum alanine transaminase (ALT) during treatment and follow-up. Before treatment, 100% of WB samples and more than 95% of Pl and PBMC samples were positive for HCV RNA. During treatment, there was progressive clearance of HCV RNA from Pl and PBMCs in SRs and CRs, but CRs had significantly more positive WB samples during and following treatment (P <.0001). At 6 months, only 10% of CR patients were positive by Pl assay, but 50% were positive by WB assay (P <.01). In the PR group, all WB samples remained positive throughout treatment, although 25% to 40% of PBMC and Pl samples became negative for HCV RNA during the first 2 months of therapy (WB > Pl or PBMC; P < .001). However, at later times during treatment most Pl and PBMC samples in the PR group were positive. Samples from the NR group showed no clearance of HCV RNA from WB, Pl, or PBMC fractions. These data document the increased sensitivity of WB assays for detecting HCV RNA in the peripheral blood of patients during interferon therapy. Furthermore, our findings suggest that WB analysis of HCV RNA may be a useful parameter to monitor in determining the end point of interferon therapy.